fm8k-0708.htm
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): July 22,
2008
(Exact
Name of Registrant as Specified in Its Charter)
(State or
Other Jurisdiction of Incorporation)
|
333-105075
|
87-0652870
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
|
|
3293
Harrison Blvd., Ste. 230, Ogden, UT
|
84403
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2.
below):
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 8.01 Other
Events
On July 22, 2008, Bio-Path
Holdings, Inc. (“Bio-Path”), announced that Dai-Shan Wong and Thomas A. Walker,
Ph.D. have joined Bio-Path’s drug development team. Mr. Wong will
serve as Bio-Path’s Director of Regulatory Affairs and Quality Control and Dr.
Walker will be the Company’s Chemistry, Manufacturing and
Controls CMC Development Specialist. The press release
relating to this announcement is attached hereto as an exhibit and is
incorporated by reference herein.
In accordance with General
Instruction B.2 of Form 8-K, the information in this Report, including Exhibit
99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, and shall not be incorporated by
reference into any registration statement or other document filed under the
Securities Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01 Financial
Statements and Exhibits
Exhibits
|
|
Exhibit
Number
|
Description
|
|
|
|
|
|
|
|
|
|
Press
Release
|
|
SIGNATURES
Pursuant to the requirements of the
Securities Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.
|
Dated: July
28, 2008
|
BIO-PATH
HOLDINGS INC.
|
|
|
|
|
|
By: /s/
Peter Nielsen
|
|
|
Chief
Executive Officer
|